This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Formula E Championship Racing (A)
Higgins, Robert F.; Weber, JamesCase HBS-819011-EEntrepreneurshipFormula E founder and CEO Alejandro Aga obtained the rights to develop a new electric car racing series from the F d ration Internationale de l'Automobile (FIA). Agag needed to develop the series from scratch-developing a race car, finding teams willing to race, cities willing to host races, and sponsors, media partners, and investors willing to fund the series. The first race was one year away. How should Agag go about developing this new seri...Starting at €8.20
-
Warren E. Buffett, 2015
Bruner, Robert F.; DuBois, JakeCase DARDEN-F-1769-EFinanceThis case was designed as an introduction to a finance course or a module on capital markets. Alternatively, it could be used as a basic introduction to methods of valuing a firm. A detailed teaching note provides instructors with a teaching plan for either scenario. Set in August 2015, students are asked to evaluate Warren Buffett’s decision to acquire the aerospace-parts supplier Precision Castparts Corporation (PCP), which would be the largest...Starting at €8.20
-
Formula E Championship Racing (B)
Higgins, Robert F.; Ma, Susie L.; Weber, JamesCase HBS-819012-EEntrepreneurshipFormula E's season three is nearly complete. CEO Alejandro Agag needs to examine his business model to ensure the racing series is positioned to grow sustainable in the years to come.Starting at €5.74
-
Warren E. Buffett, 2015 - Teaching Note
Bruner, Robert F.Teaching Note DARDEN-F-1769TN-EFinanceTeaching note for product F-1769Starting at €0.00
-
Formula E Championship Racing (A) and (B), Teaching Note
Higgins, Robert F.; Weber, JamesTeaching Note HBS-819101-EEntrepreneurshipTeaching note for cases 819011 and 819012.Starting at €0.00
-
Genzyme/Geltex Pharmaceuticals Joint Venture
Bruner, Robert F.; Bodily, Samuel E.; Jacquet, PierreCase DARDEN-F-1254-EFinanceIn March 1997, an executive vice president of Genzyme Corporation must develop the terms by which the $518 billion (revenue) firm will form a joint venture with a small biotechnology firm to make and market a new drug. The tasks for the decision maker are to estimate the enterprise value of the new joint venture, recommend how large an interest to acquire in the venture, and determine what price to pay for that interest and when. The case may be ...Starting at €8.20
-
Michael Rubin and Fanatics (A)
Higgins, Robert F.; Masko, JohnCase HBS-819077-EEntrepreneurshipIn 2016, Michael Rubin's Fanatics was the U.S.' largest sports e-commerce company, and operator of the official online store for all the major American sports leagues. That year, Fanatics began to dabble in manufacturing licensed sports merchandise, securing limited permissions from leagues to manufacture apparel in response to 'micro-moments,' sudden surges of interest in a team or player that were too abrupt for the league's usual licensees to ...Starting at €8.20
-
The Wm. Wrigley Jr. Company: Capital Structure, Valuation, and Cost of Capital (Spanish version)
Bruner, Robert F.; Carr, SeanCase DARDEN-F-1840FinanceEsta es una traducción al español de la versión del 15 de noviembre de 2005 del caso UVA-F-1482. En junio de 2002, el director de un fondo de cobertura "el inversionista activo" está considerando las posibles ganancias de aumentar la capitalización de la deuda de The Wm. Wrigley Jr. Company. Wrigley ha sido financiado de manera conservadora y, a la fecha del caso, no tiene deudas. Las tareas para el estudiante son: • Estimar el cambio potencial e...Starting at €8.20
-
-
Predilytics
Higgins, Robert F.; Lobb, AnnelenaCase HBS-813023-EEntrepreneurshipThe management team at Predilytics, a healthcare analytics firm, must decide whether to accept a Series A venture capital financing deal. The company provided analytic services to healthcare plans, typically Medicare Advantage plans, in efforts to draw conclusions from massive amounts of patient data. The company still had enough funding from a seed round to operate on a low-key basis for a few more months, but the team hoped to move forward aggr...Starting at €8.20